Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

rnal of Neuroscience (Vol 27, pp.294-

300, 2008).

- The results from the phase III ACCLAIM trial of our Celacade System

in patients with chronic heart failure were published in the

January 19th issue of The Lancet (Lancet 2008; 371: 228-36), a world-

leading medical journal. As we previously reported, while the trial

did not meet its primary endpoint, a key finding from the ACCLAIM

trial was a 39% reduction in the risk of death or cardiovascular

hospitalizations for a large pre-specified subgroup of patients with

NYHA Class II heart failure who received Celacade therapy, compared

to patients receiving placebo.

- On March 14, 2008, we had a teleconference with the FDA to discuss

and clarify the recent comments from the agency regarding the use of

a Bayesian approach for ACCLAIM II, a clinical trial which is being

planned to support an application for U.S. market approval of the

Celacade System for the treatment of patients with New York Heart

Association ("NYHA") Class II heart failure. The teleconference with

the FDA follows our announcement on March 3rd, stating that the FDA

disagrees with the use of a Bayesian approach for the planned ACCLAIM

II study. This is contrary to the FDA's original communication to us

recommending a Bayesian study design. We have prepared and submitted

a written response to the FDA's comments with respect to the use of a

Bayesian approach in ACCLAIM II.

- Grupo Ferrer Internacional, S.A. ("Ferrer"), our European marketing

partner, has the right to market Celacade for the treatment of

chronic heart failure in certain countries of the European Union

("E.U.") and Latin America. Celacade has already received E.U.

regulatory approval as a medical device under the CE Mark, which


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... LAKE, N.J., Aug. 15 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... with Warner Chilcott,s Femcon(R),FE (norethindrone and ethinyl estradiol) ... the first to file an Abbreviated New Drug,Application ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ... device company, today announced that it has ... Administration (FDA) to begin marketing additional,diameters of ... line. The Quill(TM) SRS PDO is ...
... August 16 /PRNewswire-FirstCall/,-- Santhera Pharmaceuticals (SWX: SANN, ... focus on neuromuscular diseases, and Takeda,Pharmaceutical Company ... European Medicines Agency (EMEA) has accepted the ... Santhera,s lead compound,SNT-MC17 (INN: idebenone, originally developed ...
Cached Biology Technology:Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 2Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 2Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 3Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 2European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 3European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 4European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 5European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera 6
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced ... Home Button Synaptics Fingerprint Sensor Technology Analysis" report ... Based on a totally different sensing ... first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... Facial Recognition Market 2015-2019" report to their offering. ... Facial recognition is a technology used for the identification ... feature of a person such as nose, jaw edges, ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... ANN ARBOR, Mich.---Oh, the challenges of being a neuron, ... and sensitivity to touch, sound and light, yet constantly ... How on earth are busy nerve cells supposed to ... that information overload? Somehow neurons do manage to ...
... from the University of Adelaide has added to ... warm-blooded and active. Professor Roger Seymour from ... has applied the latest theories of human and animal anatomy ... The results will be published this month in ...
... a mutation in plants that was selected twice - during ... identified as the source of variation in the evolution of ... source of key changes during the domestication of rice. ... and man-made changes was the same," said one of the ...
Cached Biology News:Scientists discover how best to excite brain cells 2Holes in fossil bones reveal dinosaur activity 2Holes in fossil bones reveal dinosaur activity 3Evolution and domestication of seed structure shown to use same genetic mutation 2
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
... Turn routine agarose gel electrophoresis into an ... system. This bufferless, pre-cast system is ideal ... restriction digests, and more. Fully automated, robot-compatible, ... E-Gel 96 system makes your high-throughput screening ...
...
Fluorescence Preserving Media, 100 mL...
Biology Products: